Prevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital

B. Janardhan\textsuperscript{1}\textsuperscript{*}, D. Shailendra\textsuperscript{2}

\textsuperscript{1}Department of Dermatology, Venereology & Leprosy (DVL), Bhaskar Medical College, Hyderabad, Telangana, India
\textsuperscript{2}Department of Pharmacology, Mediciti institute of medical sciences, Hyderabad, Telangana, India

Received: 02 November 2016
Accepted: 22 November 2016

\*Correspondence:
Dr. B. Janardhan,
E-mail: jannub6@rediffmail.com

ABSTRACT

Background: An adverse cutaneous drug reaction (ACDR) is defined as an undesirable clinical manifestation resulting from administration of a particular drug. With an ever increasing number of drugs and varied formulations being continuously made available it is important that a close watch on the risks of adverse drug reactions is looked for, to ensure safe use of medicines in the interest of the patient. In the present study our aim is to study the prevalence & pattern of cutaneous adverse drug reactions reported to department of dermatology at MediCiti Institute of Medical Sciences, Hyderabad, India.

Methods: All suspected cutaneous adverse drug reactions reported to the department of dermatology at MediCiti Institute of Medical Sciences during the two year period from January 2013 to December 2014 were included in this study. A thorough clinical examination of all these cases & details related to the drug use and clinical manifestations of the cutaneous adverse drug reaction were documented using a structured proforma. Naranjo scale was used to assess causality in all the causes of cutaneous adverse drug reactions.

Results: The mean age of the patients was 42 years (age range: 1-64 years). Most of them were in the age group of 30-39 years. The male to female ratio was 1.78:1. The most common type of skin eruptions observed were maculopapular rash (35.55%), urticaria (26.19%) and fixed drug eruption (17.87%). The mean duration between drug intake and appearance of rash was 4 days (range: 1-120 days).

Conclusions: The pattern of ACDRs and the drugs causing them in this study were similar to that reported in other studies both in terms of disease burden and clinical pattern. Knowledge of adverse cutaneous drug reactions will help to identify common medications contributing to dermatological reactions, so as to anticipate, prevent and limit their undue consequences.

Keywords: Adverse cutaneous drug reactions, Drug rash, Drug reaction

INTRODUCTION

Cutaneous adverse drug reactions are part of skin problems reported to dermatology clinics. Systematic monitoring and surveillance of adverse drug reactions will help in ensuring safer prescription and limit the adverse effects of drugs with their undue consequences. We analysed systematically documented data on cutaneous adverse drug reactions reporting at our centre.

The main aim of this study was to estimate the burden of cutaneous adverse drug reactions and to analyse the nature and causality of cutaneous adverse drug reactions in a tertiary care hospital.

The objectives of the study was to estimate the prevalence of adverse cutaneous drug reactions (ACDR) presenting to department of Dermatology at a tertiary
care hospital and to determine the pattern of ACDR and to identify the putative aetiological agents causing them.

METHODS

All patients with cutaneous adverse drug reactions presenting to the dermatology department at MediCiti Institute of Medical Sciences from January 2013 to December 2014 were included in this study. All cases of suspected drug rash presenting to the dermatology department either self-reported or referral from other departments were examined by a dermatologist. A detailed history including medication use was collected and a clinical diagnosis was made after thorough clinical examination and subjected to relevant investigations wherever required. The details of cutaneous manifestation, medication use, were recorded in the adverse drug reaction reporting form used in the National Pharmacovigilance program of India. Naranjo scale was used for assessing causality of suspected individual cutaneous adverse drug reactions. The study was approved by the Institution Ethics Committee.

RESULTS

Total number of patients reported at our centre during the period from January 2013 to December 2014 was 44,408. A total of 481 suspected cutaneous adverse drug reactions were reported during the said time period. The prevalence of cutaneous adverse drug reactions was 1.08%. The age group in this study ranged from 1 year to 64 years with mean age of 42 years. The number of male patients 308 (64%) and female were 173 (36%), with a male to female ratio of 1.78:1. The mean duration between drug intake and appearance of rash was 4 days (1-120 days). The proportions of various cutaneous adverse drug reactions are shown in Table 1.

The distribution of various cutaneous drug reactions by suspected medication was provided in Table 2.

DISCUSSION

Cutaneous adverse drug reactions account for a major portion of drug reactions. Most cutaneous adverse drug reactions could impose significant physical, mental and economic burden on the patient while others may end fatally.

The prevalence of cutaneous adverse drug reactions in our study was 1.08% which is similar to that reported in literature. Studies have reported the burden of ACDRs in developed countries as 1–3% and in developing countries between 2-5%. We observed a male: female ratio of 1.78:1 in the cases that reported with suspected cutaneous adverse drug reactions. Slight male preponderance in cutaneous adverse drug reactions was reported by Sharma et al. A systematic review done by Patel et al concluded that association of gender is inconsistent in published literature & reported that the male preponderance to cutaneous adverse drug reactions in India could be due to the gender distribution of Indian population.

The most common cutaneous adverse drug reaction observed in our study was maculopapular eruptions (34.3%). The most common drug causing maculopapular eruption was Amoxicillin, followed by Ampicillin, Cephalosporins, Phenytoin and Carbamazepine. Similar to our observation, several studies reported maculopapular rash as the most common cutaneous adverse drug reaction. The time of onset of maculopapular eruption after the suspected medication intake ranged from 1 day to 7 days in our study.

Table 1: Distribution of various cutaneous adverse drug reactions.

| Nature of Lesion                                      | No. of cases | Percentage |
|-------------------------------------------------------|--------------|------------|
| Maculopapular eruptions                               | 171          | 35.55      |
| Urticaria                                             | 126          | 26.19      |
| Fixed drug eruptions (FDE)                            | 86           | 17.87      |
| Drug induced vasculitis                              | 24           | 4.98       |
| Erythema multiforme(EMF)                              | 20           | 4.15       |
| Drug Reaction with eosinophilia and systemic symptoms (DRESS) | 20           | 4.15       |
| Acute generalised exanthematous pustulosis (AGEP)     | 15           | 3.11       |
| Lichenoid eruptions                                   | 10           | 2.07       |
| Stevens Johnson Syndrome (SJS)                        | 05           | 1.03       |
| SJS/TEN overlap syndrome                              | 02           | 0.41       |
| Toxic epidemic necrolysis (TEN)                       | 02           | 0.41       |
| Total                                                 | 481          | 100        |

The second most common cutaneous adverse drug reaction observed in our study was urticaria comprising 26.2%. Non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the most cases of urticarial (40%), followed by Sulfonamides, Penicillin, Cephalosporins, Enalapril, Cetrizine and radio-contrast media. All of these medications were reported to be associated with urticaria in several previous studies. Antihistamine like Cetrizine causing urticaria was observed in 4 cases in our study. Similar observation was reported by Calista et al.

International Journal of Research in Dermatology | January-March 2017 | Vol 3 | Issue 1 | Page 75
Fixed drug eruption comprised 17.9% of the total cutaneous adverse drug reactions in our study. Diclofenac contributed to the highest number of fixed drug eruptions followed by Cotrimoxazole, Ciprofloxacin, Ibuprofen, Ofloxacin, Phenytoin, Metronidazole, Carbamazepine, Levofloxacin and Sparfloxacin. These findings are in concordance with other studies.12-14

Table 2: Distribution of cutaneous adverse drug reactions by suspected drug.

| S.no. | Type of cutaneous adverse drug reaction | Total no. of cases (N) | Name of the drug          | No. of cases (n) | Percentage (%) |
|-------|----------------------------------------|------------------------|---------------------------|------------------|----------------|
| 1     | Maculo-Papular eruptions               | 171                    | Amoxicillin               | 68               | 39.77          |
|       |                                        |                        | Ampicillin                | 34               | 19.88          |
|       |                                        |                        | Cephalosporins            | 38               | 22.22          |
|       |                                        |                        | Phenytoin                 | 23               | 13.45          |
|       |                                        |                        | Carbamazepine             | 08               | 4.68           |
| 2     | Urticaria                              | 126                    | NSAIDS                    | 54               | 42.85          |
|       |                                        |                        | Sulfonamides              | 22               | 17.46          |
|       |                                        |                        | Penicillin                | 16               | 12.69          |
|       |                                        |                        | Cephalosporin             | 14               | 11.11          |
|       |                                        |                        | Enalapril                 | 14               | 11.11          |
|       |                                        |                        | Cetirizine                | 04               | 3.17           |
|       |                                        |                        | Radio-contrast media      | 02               | 1.58           |
| 3     | Fixed drug eruptions                   | 86                     | Diclofenac                | 16               | 18.6           |
|       |                                        |                        | Cotrimoxazole             | 14               | 16.27          |
|       |                                        |                        | Ciprofloxacin             | 12               | 13.95          |
|       |                                        |                        | Ibuprofen                 | 10               | 11.62          |
|       |                                        |                        | Ofloxacin                 | 09               | 10.46          |
|       |                                        |                        | Phenytoin                 | 08               | 9.30           |
|       |                                        |                        | Metronidazole             | 06               | 6.97           |
|       |                                        |                        | Carbamazepine             | 05               | 5.81           |
|       |                                        |                        | Levofloxacin              | 04               | 4.65           |
|       |                                        |                        | Gatifloxacin              | 02               | 2.32           |
| 4     | Vasculitis                             | 24                     | Phenytoin                 | 12               | 50.0           |
|       |                                        |                        | Enalapril                 | 08               | 33.33          |
|       |                                        |                        | Carbamazepine             | 04               | 16.67          |
| 5     | Drug reaction with eosinophilia and systemic symptoms (DRESS) | 20 | Cotrimoxazole | 07 | 35.0 |
|       |                                        |                        | Phenytoin                 | 06 | 30.0 |
|       |                                        |                        | Dapsone                   | 04 | 20.0 |
|       |                                        |                        | Carbamazepine             | 03 | 15.0 |
| 6     | Acute generalized exanthematous pustulosis | 15 | Amoxicillin | 04 | 26.67 |
|       |                                        |                        | Ampicillin                | 04 | 26.67 |
|       |                                        |                        | Cephalexin                | 04 | 26.67 |
|       |                                        |                        | Cefpodoxime               | 02 | 13.33 |
|       |                                        |                        | Doxycycline               | 01 | 6.67 |
| 7     | Lichenoid eruptions                    | 10                     | Hydroxychloroquine        | 07 | 70.0 |
|       |                                        |                        | Diclofenac                | 02 | 20.0 |
|       |                                        |                        | Atenolol                  | 01 | 10.0 |
| 8     | Erythema multiforme                    | 20                     | NSAIDs                    | 12 | 60.0 |
|       |                                        |                        | Sulfonamides              | 06 | 30.0 |
|       |                                        |                        | Phenobarbitone            | 02 | 10.0 |
| 9     | Stevens Johnson syndrome ( SJ) & SJS/TEN | 5+2 | Phenytoin | 04 | 57.14 |
|       |                                        |                        | Carbamazepine             | 03 | 42.85 |
|       |                                        |                        | carbamazepine             | 01 | 50.0 |
| 10    | Toxic epidermal necrolysis (TEN)       | 2                      | Phenytoin                 | 01 | 50.0 |
A study done by Nandha et al in north India observed predominantly maculopapular rash followed by fixed drug eruption & urticaria, whereas in our study we noted maculopapular rash dominance followed by urticaria & fixed drug eruption.\textsuperscript{15}

Drug induced vasculitis comprised 4.98% of the total cutaneous adverse drug reactions. The most common offending agent associated with drug induced vasculitis was Phenytoin, followed by Enalapril and Carbamazepine.

Drug Reaction with eosinophilia and systemic symptoms (DRESS) comprised 4.15% of the cutaneous adverse drug reactions. The most common drugs suspected was Cotrimoxazole followed by Phenytoin, Dapsone and Carbamazepine. DRESS has been shown to be associated with the use of antiepileptics and sulphur compounds. Similar observations made by Akpinar et al.\textsuperscript{14}

Acute Generalized exanthematous pustulosis comprised 3.11% of the total cutaneous adverse drug reactions. Amoxicillin was associated with the most number of cases followed by Ampicillin, Cephalexin, Cepodoxime and Doxycline. These observations are similar to those observed by Sidoroff et al.\textsuperscript{16}

Erythema multiforme comprised 4.15% of the adverse cutaneous drug reactions. Drugs noticed are NSAIDs, sulphonamides and phenobarbitone. Our observations are in concordance with previous studies in India which have reported an incidence of Erythema multiforme ranging from 0.4% to 3.57%.\textsuperscript{17,18}

Lichenoid eruptions comprised 2.07% of the cutaneous adverse drug reactions. Hydroxychloroquine was associated with the majority cases, followed by Diclofenac and Atenolol.

Stevens Johnson syndrome (SJS) comprised a small fraction (1.03%) of reported cutaneous adverse drug reactions. About 57% of SJS was associated with the use of Phenytoin and 43% with the use of Carbamazepine. Toxic epidermal necrolysis (TEN) comprised 0.4% of the total cutaneous adverse drug reactions. There were only 2 cases of TEN, one each associated with the use of Phenytoin and Carbamazepine. SJS/TEN overlap syndrome was seen in 2 patients only. These findings are in concordance with reports implicating antiepileptics, similar to review done by Patel et al.\textsuperscript{19}

The patients who had adverse drug reaction like toxic epidermal necrolysis, Stevens Johnson syndrome, SJS/TEN overlap syndrome, DRESS syndrome & acute generalised exanthematous pustulosis were treated as in-patients. One patient with TEN survived and the other died. The Scorten in the patient who survived was 3, whereas the Scorten was 4 in the patient who died.

All the cutaneous adverse drug reactions noted in our study had a score ranging from 1-4 using the Naranjo algorithm for causality assessment.\textsuperscript{20} Thus, suggesting that the cutaneous adverse drug reactions noted in our study were probable in terms of causality.

**CONCLUSION**

The pattern of cutaneous adverse drug reactions observed in this study are similar to that reported in various studies in India. Further, the medications predominantly antibiotics & anticonvulsants that were found to be possibly associated with the cutaneous adverse drug reactions in our study have been reported in literature to be similarly associated with cutaneous drug reactions both in India and abroad.

**Funding:** No funding sources

**Ethical approval:** The study was approved by the institutional ethics committee

**REFERENCES**

1. Pudukadan D, Thappa DM. Adverse cutaneous drug reactions: Clinical pattern and causative agents in a tertiary care center in South India. Indian J Dermatol Venereol Leprol. 2004;70:20-4.
2. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern & causative agents--a 6 year series from Chandigarh, India. J Post grad Med. 2001;47(2):95-9.
3. Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389-98.
4. Ding WY, Lee CK, Choone SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010;49:834-41.
5. Choone SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol. 2012;78:734-9.
6. Puavilai S, Choohakarn C. Drug eruptions in Bangkok: A 1-year study at Ramathibodi Hospital. Int J Dermatol. 1998;37:747-51.
7. Chatterjee S, Ghosh AP, Barbhuiya J, Dey SK. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol. 2006;38:429–31.
8. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137:765-70.
9. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents--a 6 year series from Chandigarh. Indian J Post grad Med. 2001;47(2):95-9.
10. Anjaneyan G, Gupta R, Vora R. Clinical study of adverse cutaneous drug reactions at a rural based tertiary care centre in Gujarat. Natl J Physiol Pharm Pharmacol. 2013;3:129–36.
11. Calista D, Schianchi S, Morri M. Urticaria induced by cetirizine. Br J Dermatol. 2001;144:196.
12. Brahma DK, Sangma KA, Lynrah KG, Marak MD, Wahlang JB, Bhattacharyya H, et al. Adverse cutaneous drug reactions: A one year survey at dermatology outpatient clinic in a tertiary care hospital. Int J Pharm World Res. 2012;3:1–9.
13. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833.
14. Akpinar F, Dervis E. Drug Eruptions: 8-year Study Including 106 In patients at a Dermatology Clinic in Turkey. Indian J Dermatol. 2012;57(3):194-8.
15. Nandha R, Gupta A, Hashmi A. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective. In J Appl Basic Med Res. 2011;1(1):50-3.
16. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavink JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (Euro SCAR). Br J Dermatol. 2007;157(5):989-96.
17. Jhaj R, Uppal R, Malhotra S, Bhargava VK. Cutaneous adverse reactions in in-patients in a tertiary care hospital. Indian J Dermatol Venereol Leprol. 1999;65:14–7.
18. Mahapatra S, Keshri PU. Adverse cutaneous drug reactions in a tertiary care center patients: A prospective analysis. J App Pharm Sci. 2012;2:96–8.
19. Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389-98.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Cite this article as: Janardhan B, Shailendra D. Prevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital. Int J Res Dermatol 2017;3:74-8.